Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:DNANASDAQ:IMCRNASDAQ:KNSANASDAQ:MIRM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNAGinkgo Bioworks$11.96+5.3%$8.05$5.00▼$16.85$700.66M1.481.43 million shs357,578 shsIMCRImmunocore$33.48+1.9%$32.17$23.15▼$41.54$1.68B0.77346,708 shs54,327 shsKNSAKiniksa Pharmaceuticals International$27.80+2.1%$27.09$17.82▼$30.69$2.03B0.05548,605 shs251,433 shsMIRMMirum Pharmaceuticals$49.11+1.5%$45.90$33.45▼$54.23$2.43B0.97463,220 shs66,190 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNAGinkgo Bioworks+0.71%+23.96%+63.36%+89.50%-14.97%IMCRImmunocore+4.65%+2.59%-10.00%+11.59%-9.85%KNSAKiniksa Pharmaceuticals International-1.55%-6.26%-0.69%+24.67%+51.33%MIRMMirum Pharmaceuticals-4.91%-5.32%+9.13%+7.53%+41.66%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDNAGinkgo Bioworks0.8148 of 5 stars0.82.00.00.01.92.51.3IMCRImmunocore2.4455 of 5 stars4.30.00.00.02.52.50.0KNSAKiniksa Pharmaceuticals International3.553 of 5 stars3.54.00.00.02.73.30.6MIRMMirum Pharmaceuticals3.6459 of 5 stars3.60.00.04.21.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDNAGinkgo Bioworks 1.67Reduce$5.77-51.78% DownsideIMCRImmunocore 2.55Moderate Buy$58.8975.89% UpsideKNSAKiniksa Pharmaceuticals International 3.00Buy$38.8039.56% UpsideMIRMMirum Pharmaceuticals 3.13Buy$65.5033.39% UpsideCurrent Analyst Ratings BreakdownLatest DNA, MIRM, KNSA, and IMCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025IMCRImmunocoreHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$100.005/27/2025IMCRImmunocoreDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$65.005/19/2025MIRMMirum PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$73.005/13/2025MIRMMirum PharmaceuticalsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingStrong-Buy ➝ Strong-Buy5/13/2025MIRMMirum PharmaceuticalsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$73.00 ➝ $77.005/9/2025MIRMMirum PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$74.00 ➝ $76.005/8/2025IMCRImmunocoreOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$85.00 ➝ $86.004/29/2025KNSAKiniksa Pharmaceuticals InternationalJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$40.00 ➝ $45.004/16/2025KNSAKiniksa Pharmaceuticals InternationalWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$34.00 ➝ $34.004/14/2025IMCRImmunocoreJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$54.00 ➝ $50.004/10/2025IMCRImmunocoreNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$71.00 ➝ $71.00(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDNAGinkgo Bioworks$227.04M3.08N/AN/A$13.17 per share0.91IMCRImmunocore$310.20M5.42N/AN/A$7.20 per share4.65KNSAKiniksa Pharmaceuticals International$423.24M4.79N/AN/A$6.60 per share4.21MIRMMirum Pharmaceuticals$336.89M7.22N/AN/A$4.70 per share10.45Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDNAGinkgo Bioworks-$547.03M-$9.16N/AN/AN/A-198.84%-52.35%-27.14%8/14/2025 (Estimated)IMCRImmunocore-$51.09M-$0.43N/AN/AN/A-6.48%-5.86%-2.09%8/6/2025 (Estimated)KNSAKiniksa Pharmaceuticals International-$43.19M-$0.25N/A111.20N/A-3.52%-3.83%-2.98%7/22/2025 (Estimated)MIRMMirum Pharmaceuticals-$87.94M-$1.61N/AN/AN/A-20.39%-33.63%-11.50%8/6/2025 (Estimated)Latest DNA, MIRM, KNSA, and IMCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/22/2025Q2 2025KNSAKiniksa Pharmaceuticals International$0.08N/AN/AN/AN/AN/A5/14/2025Q1 2025MIRMMirum Pharmaceuticals-$0.35-$0.30+$0.05-$0.30$98.47 million$111.59 million5/7/2025Q1 2025IMCRImmunocore-$0.35$0.10+$0.45$0.10$108.82 million$125.13 million5/6/2025Q1 2025DNAGinkgo Bioworks-$1.23-$1.58-$0.35-$1.68$38.70 million$48.32 million4/29/2025Q1 2025KNSAKiniksa Pharmaceuticals International$0.02$0.11+$0.09$0.11$128.35 million$137.79 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDNAGinkgo BioworksN/AN/AN/AN/AN/AIMCRImmunocoreN/AN/AN/AN/AN/AKNSAKiniksa Pharmaceuticals InternationalN/AN/AN/AN/AN/AMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDNAGinkgo BioworksN/A4.884.88IMCRImmunocore1.036.366.31KNSAKiniksa Pharmaceuticals InternationalN/A3.663.43MIRMMirum Pharmaceuticals1.323.223.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDNAGinkgo Bioworks78.63%IMCRImmunocore84.50%KNSAKiniksa Pharmaceuticals International53.95%MIRMMirum PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipDNAGinkgo Bioworks9.72%IMCRImmunocore10.40%KNSAKiniksa Pharmaceuticals International53.48%MIRMMirum Pharmaceuticals22.87%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDNAGinkgo Bioworks64058.53 million52.84 millionOptionableIMCRImmunocore32050.23 million45.01 millionOptionableKNSAKiniksa Pharmaceuticals International22072.97 million33.95 millionOptionableMIRMMirum Pharmaceuticals14049.53 million38.21 millionOptionableDNA, MIRM, KNSA, and IMCR HeadlinesRecent News About These CompaniesMirum Pharmaceuticals (NASDAQ:MIRM) Upgraded by Wall Street Zen to Buy RatingJune 28, 2025 | americanbankingnews.comMirum Pharmaceuticals (NASDAQ:MIRM) Stock Rating Upgraded by Wall Street ZenJune 28, 2025 | marketbeat.com5,376 Shares in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Acquired by Palumbo Wealth Management LLCJune 24, 2025 | marketbeat.comGAMMA Investing LLC Buys 5,466 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)June 22, 2025 | marketbeat.comSG Americas Securities LLC Buys 12,204 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)June 19, 2025 | marketbeat.comLiver Drug Stock Rockets 236% Amid FDA Approval As Sales Accelerate; Funds Load UpJune 17, 2025 | msn.comBrokers Set Expectations for MIRM FY2026 EarningsJune 11, 2025 | marketbeat.comMirum Pharmaceuticals Inc.June 11, 2025 | barrons.comMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 10, 2025 | businesswire.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Consensus Recommendation of "Buy" from AnalystsJune 8, 2025 | marketbeat.comWhy Is Mirum Pharmaceuticals (MIRM) Down 1.3% Since Last Earnings Report?June 6, 2025 | zacks.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $3.06 Million Stock Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)June 6, 2025 | marketbeat.comSecure Asset Management LLC Purchases 8,990 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)June 4, 2025 | marketbeat.comSquarepoint Ops LLC Takes Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)June 2, 2025 | marketbeat.comMirum Pharmaceuticals’ SWOT analysis: rare disease stock shows growth potentialMay 27, 2025 | investing.comMirum Pharmaceuticals at RBC Conference: Strategic Growth HighlightsMay 22, 2025 | uk.investing.comMirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal OfficerMay 19, 2025 | businesswire.comMirum Pharmaceuticals to Participate in Upcoming Investor ConferencesMay 14, 2025 | businesswire.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q1 2025 Earnings Call TranscriptMay 14, 2025 | insidermonkey.comMirum's Q1 Earnings Beat Estimates, 2025 Revenue View RaisedMay 8, 2025 | zacks.comMirum Pharmaceuticals Inc (MIRM) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ...May 8, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDNA, MIRM, KNSA, and IMCR Company DescriptionsGinkgo Bioworks NYSE:DNA$11.94 +0.58 (+5.08%) As of 10:58 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Immunocore NASDAQ:IMCR$33.48 +0.64 (+1.95%) As of 10:58 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.Kiniksa Pharmaceuticals International NASDAQ:KNSA$27.77 +0.53 (+1.94%) As of 10:58 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.Mirum Pharmaceuticals NASDAQ:MIRM$49.10 +0.72 (+1.48%) As of 10:58 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Why Realty Income’s 5.59% Yield Makes It a Must-Buy REIT Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
